Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATH-19: Tocilizumab for COVID-19 Pneumonia
NCT04445272Phase 2Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in COVID-19 pneumonia, sponsored by Fundación SEIMC-GeSIDA. Started May 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04445272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445272.